Xin Zengfeng, Chen Junhua, Huang Fengbo, Guo Siyu, Yao Yihan, Tang Yang, Li Hang, Lv Qinghua, Zhang Ting
Department of Orthopedic Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, University, Hangzhou, China.
Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, China.
Heliyon. 2024 Jul 2;10(13):e33851. doi: 10.1016/j.heliyon.2024.e33851. eCollection 2024 Jul 15.
Heterotopic ossification refers to the pathological formation of extra-skeletal bone. It is a common complication of trauma or surgery that can cause disability and has no definitive cure. Furthermore, the mechanisms underlying chronic inflammation during ossification remain unclear. Therefore, this study aimed to elucidate the systemic immune microenvironment status of heterotopic ossification and identify biomarkers of therapeutic efficacy and recurrence. A combination of stereoarthrolysis with prophylactic radiotherapy and non-steroidal anti-inflammatory drugs was used to treat patients with heterotopic ossification. Changes were observed in peripheral blood lymphocyte levels after treatment. The number of IFNγCD8T cells (3.753 % vs 12.90 %, P < 0.0001) and IL17CD4T cells (3.420 % vs 5.560 %, P = 0.0281) were was higher in the peripheral blood of relapsed patients with heterotopic ossification than in that of non-relapsed patients. Similarly, the number of these cells was elevated in patients who developed heterotopic ossification after posttraumatic elbow surgery. Peripheral CD8T cells derived from patients with this pathology promoted osteogenesis through IFNγ expression . Our findings demonstrate that IFNγCD8T cells and IL17CD4T cells are potential biomarkers of heterotopic ossification after posttraumatic elbow surgery. Furthermore, these cells can be used to predict therapeutic efficacy and relapse after combination therapy.
异位骨化是指骨骼外病理性骨形成。它是创伤或手术的常见并发症，可导致残疾且尚无根治方法。此外，骨化过程中慢性炎症的潜在机制仍不清楚。因此，本研究旨在阐明异位骨化的全身免疫微环境状态，并确定治疗效果和复发的生物标志物。采用关节松解术联合预防性放疗和非甾体抗炎药治疗异位骨化患者。观察治疗后外周血淋巴细胞水平的变化。异位骨化复发患者外周血中IFNγCD8T细胞数量（3.753%对12.90%，P<0.0001）和IL17CD4T细胞数量（3.420%对5.560%，P=0.0281）高于未复发患者。同样，创伤后肘部手术后发生异位骨化的患者中这些细胞的数量也升高。源自该病理患者的外周CD8T细胞通过IFNγ表达促进成骨。我们的研究结果表明，IFNγCD8T细胞和IL17CD4T细胞是创伤后肘部手术后异位骨化的潜在生物标志物。此外，这些细胞可用于预测联合治疗后的治疗效果和复发情况。
